Name | Number of supported studies | Average coverage | |
---|---|---|---|
microglial cell | 11 studies | 27% ± 7% | |
macrophage | 4 studies | 26% ± 10% | |
endothelial cell | 3 studies | 18% ± 2% | |
epithelial cell | 3 studies | 18% ± 1% | |
GABAergic neuron | 3 studies | 27% ± 3% | |
glutamatergic neuron | 3 studies | 39% ± 7% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 6 studies | 23% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 1059.48 | 226 / 226 | 100% | 10.17 | 406 / 406 |
lung | 100% | 2049.47 | 578 / 578 | 100% | 17.06 | 1155 / 1155 |
ovary | 100% | 1409.89 | 180 / 180 | 100% | 12.02 | 430 / 430 |
prostate | 100% | 1351.26 | 245 / 245 | 100% | 13.35 | 502 / 502 |
uterus | 100% | 1236.79 | 170 / 170 | 100% | 16.65 | 459 / 459 |
esophagus | 100% | 1133.95 | 1444 / 1445 | 100% | 15.72 | 183 / 183 |
thymus | 100% | 1642.43 | 653 / 653 | 100% | 15.04 | 604 / 605 |
skin | 100% | 2133.75 | 1809 / 1809 | 100% | 15.12 | 471 / 472 |
stomach | 100% | 1021.61 | 358 / 359 | 100% | 13.43 | 286 / 286 |
intestine | 100% | 1229.93 | 966 / 966 | 100% | 14.34 | 525 / 527 |
bladder | 100% | 1127.81 | 21 / 21 | 100% | 15.71 | 502 / 504 |
brain | 100% | 1520.76 | 2631 / 2642 | 100% | 22.17 | 705 / 705 |
breast | 100% | 1340.38 | 459 / 459 | 100% | 15.27 | 1113 / 1118 |
adrenal gland | 100% | 2776.01 | 258 / 258 | 99% | 14.14 | 228 / 230 |
kidney | 100% | 988.63 | 89 / 89 | 99% | 16.17 | 889 / 901 |
pancreas | 98% | 748.13 | 321 / 328 | 99% | 16.00 | 177 / 178 |
adipose | 100% | 1316.64 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 14.28 | 29 / 29 |
spleen | 100% | 2066.39 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 15.41 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.87 | 1 / 1 |
blood vessel | 100% | 914.83 | 1330 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 1168.38 | 799 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 1469.50 | 917 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 11.19 | 78 / 80 |
heart | 97% | 650.51 | 839 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006640 | Biological process | monoacylglycerol biosynthetic process |
GO_0022008 | Biological process | neurogenesis |
GO_0010898 | Biological process | positive regulation of triglyceride catabolic process |
GO_0019369 | Biological process | arachidonic acid metabolic process |
GO_0050727 | Biological process | regulation of inflammatory response |
GO_0046340 | Biological process | diacylglycerol catabolic process |
GO_1901696 | Biological process | cannabinoid biosynthetic process |
GO_0001516 | Biological process | prostaglandin biosynthetic process |
GO_0007405 | Biological process | neuroblast proliferation |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005886 | Cellular component | plasma membrane |
GO_0005765 | Cellular component | lysosomal membrane |
GO_0004806 | Molecular function | triglyceride lipase activity |
GO_0047372 | Molecular function | acylglycerol lipase activity |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0016298 | Molecular function | lipase activity |
Gene name | DAGLB |
Protein name | Diacylglycerol lipase beta Diacylglycerol lipase-beta (DAGL-beta) (DGL-beta) (EC 3.1.1.116) (KCCR13L) (PUFA-specific triacylglycerol lipase) (EC 3.1.1.3) (Sn1-specific diacylglycerol lipase beta) sn-1-specific diacylglycerol lipase (EC 3.1.1.116) |
Synonyms | |
Description | FUNCTION: Lipase that catalyzes the hydrolysis of arachidonic acid (AA)-esterified diacylglycerols (DAGs) to produce the principal endocannabinoid, 2-arachidonoylglycerol (2-AG) which can be further cleaved by downstream enzymes to release arachidonic acid (AA) for cyclooxygenase (COX)-mediated eicosanoid production . Preferentially hydrolyzes DAGs at the sn-1 position in a calcium-dependent manner and has negligible activity against other lipids including monoacylglycerols and phospholipids . Plays a key role in the regulation of 2-AG and AA pools utilized by COX1/2 to generate lipid mediators of macrophage and microglia inflammatory responses. Functions also as a polyunsaturated fatty acids-specific triacylglycerol lipase in macrophages. Plays an important role to support the metabolic and signaling demands of macrophages (By similarity). . |
Accessions | F8WBN0 Q8NCG7 ENST00000436575.5 E7ET49 C9JA85 ENST00000432248.1 ENST00000454738.5 ENST00000297056.11 [Q8NCG7-1] ENST00000425398.6 [Q8NCG7-4] |